A Study of PF-07260437 in Advanced or Metastatic Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 7, 2021

Primary Completion Date

October 17, 2023

Study Completion Date

October 17, 2023

Conditions
Ovarian NeoplasmsEndometrial NeoplasmsBreast Neoplasms
Interventions
DRUG

PF-07260437

B7-H4 x CD3 bi-specific mAb

DIAGNOSTIC_TEST

B7-H4 IHC

B7-H4 expression

Trial Locations (15)

10461

Montefiore Einstein Center for Cancer Care, The Bronx

33612

Moffitt Cancer Center at McKinley Campus, Tampa

Moffitt Cancer Center, Tampa

60451

University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox

60462

The University of Chicago Medicine Center of Advanced Care Orland Park, Orland Park

60637

University of Chicago Medical Center, Chicago

78229

NEXT Oncology, San Antonio

91010

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte

98026

Swedish Cancer Institute Edmonds Campus, Edmonds

98104

Swedish Cancer Institute, Seattle

98109

Fred Hutchinson Cancer Center, Seattle

98195

University of Washington Medical Center - Mountlake, Seattle

00935

Pan American Center for Oncology Trials, LLC, Rio Piedras

Pan American Center for Oncology Trials- Hospital Oncologico, Rio Piedras

Pan American Center for Oncology Trials, Rio Piedras

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05067972 - A Study of PF-07260437 in Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter